We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current OKYO market cap is 43.96M. The company's latest EPS is USD -0.4972 and P/E is -2.53.
| Quarter End | |||||
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | USD (US$) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.22M | -2.16M | -3.73M | -9.83M | -14.32M |
| Net Income | -1.21M | -2.26M | -3.98M | -11.01M | -16.83M |
| Quarter End | |||||
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | USD (US$) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | USD (US$) | |
| Total Assets | 483k | 5.14M | 3.27M | 4.22M | 1.54M |
| Total Liabilities | 596k | 1.28M | 1.03M | 5.88M | 7.42M |
| Total Equity | -113k | 3.85M | 2.24M | -1.66M | -5.88M |
| Market Cap | 43.96M |
| Price to Earnings Ratio | -2.53 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 51.64 |
| Price to Book Ratio | -7.25 |
| Dividend Yield | - |
| Shares Outstanding | 33.84M |
| Average Volume (1 week) | 173.26k |
| Average Volume (1 Month) | 94.9k |
| 52 Week Change | -10.41% |
| 52 Week High | 1.90 |
| 52 Week Low | 0.8075 |
| Spread (Intraday) | 0.14 (10%) |
| Company Name | OKYO Pharma Ltd |
| Address |
martello court guernsey GY1 3HB |
| Website | https://www.okyopharma.com |
| Industry | miscellaneous metal ores,nec (1099) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
